Diaceutics (LON:DXRX) Issues Earnings Results

Diaceutics (LON:DXRX) announced its earnings results on Tuesday. The company reported GBX (3.27) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Diaceutics had a return on equity of 0.25% and a net margin of 0.25%.

Diaceutics Stock Performance

Shares of DXRX stock opened at GBX 186.80 on Wednesday. The company has a current ratio of 3.43, a quick ratio of 9.92 and a debt-to-equity ratio of 2.85. The stock has a 50 day simple moving average of GBX 145.97 and a 200-day simple moving average of GBX 150.95. The company has a market cap of £158.52 million, a price-to-earnings ratio of 1,698.18 and a beta of 0.88. Diaceutics has a 12-month low of GBX 125 and a 12-month high of GBX 190.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group reissued a “buy” rating and issued a GBX 215 target price on shares of Diaceutics in a report on Tuesday. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Diaceutics currently has a consensus rating of “Buy” and an average price target of GBX 215.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.